(NASDAQ: CDXS) Codexis's forecast annual revenue growth rate of 15.06% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.66%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Codexis's revenue in 2026 is $78,092,000.On average, 9 Wall Street analysts forecast CDXS's revenue for 2026 to be $6,882,597,157, with the lowest CDXS revenue forecast at $6,413,661,768, and the highest CDXS revenue forecast at $7,234,457,768. On average, 8 Wall Street analysts forecast CDXS's revenue for 2027 to be $8,244,500,420, with the lowest CDXS revenue forecast at $7,215,369,488, and the highest CDXS revenue forecast at $10,394,022,436.
In 2028, CDXS is forecast to generate $11,141,192,217 in revenue, with the lowest revenue forecast at $8,221,958,071 and the highest revenue forecast at $14,189,863,074.